COVID-19 and Disease-Modifying Anti-rheumatic Drugs

PURPOSE OF REVIEW: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. RECENT FINDINGS: In patients with autoimmune diseases, baseline glucocorticoid use is...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Silva, Kristin M., Wallace, Zachary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Infections and Arthritis (K Winthrop, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065312/
https://www.ncbi.nlm.nih.gov/pubmed/33893890
http://dx.doi.org/10.1007/s11926-021-00998-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065312/
https://www.ncbi.nlm.nih.gov/pubmed/33893890
http://dx.doi.org/10.1007/s11926-021-00998-9

Ejemplares similares